Screening, identification, and experimental validation of SUMOylation biomarkers in Parkinson's disease.

Journal: Hereditas
Published Date: Aug 8, 2025

Abstract

BACKGROUND: Parkinson's disease (PD) is a common neurodegenerative disorder. The role of protein post-translational modifications (PTMs), especially small ubiquitin-like modifier (SUMO) conjugation (SUMOylation), in PD pathogenesis remains unclear. This study aimed to investigate the relationship between SUMOylation and PD.

Authors

  • Yifo Wei
    Xi'an Hospital of Traditional Chinese Medicine, Xi'an, China.
  • Xinning Zhang
    Xi'an Hospital of Traditional Chinese Medicine, Xi'an, China.
  • Rui Zuo
    Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
  • Wenxin Dang
    Xi'an Hospital of Traditional Chinese Medicine, Xi'an, China.
  • Lu Chen
    Ultrasonic Department, Zhongda Hospital Affiliated to Southeast University, Nanjing, 210009, China.
  • Fan Liu
    Hunan Provincial Key Laboratory of Dong Medicine, Hunan University of Medicine, Huaihua, China.
  • Jia Yao
    Experimental Center, Xi'an Hospital of Traditional Chinese Medicine, No.69 Feng Cheng 8th Road, Weiyang District, Xi'an, 710021, China.
  • Weizheng Ran
    The First Medical Center of PLA General Hospital, Beijing, China.
  • Zhigang Chen
    The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, #7 Jinsui Road, Guangzhou, Guangdong 510230, China.
  • Xiaoyan Wang
    Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
  • Furong Lv
    Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Yue Yu
    Department of Mathematics, Lehigh University, Bethlehem, PA, USA.

Keywords

External Resources

Popular Topics
Recent Journals